Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SH003 and Docetaxel in Advanced Solid Cancer
NCT04360317Phase 1Unknown
- Sponsor
- Kyung Hee University Medical Center
- Start
- Jun 2020
- Primary completion
- May 2021
- Modality
- Prophylactic Vaccines, Small Molecules, Therapeutic Vaccines
01
Overview
Phase 1, open-label, single-arm trial of SH003 in lung cancer and breast cancer, sponsored by Kyung Hee University Medical Center. Primary endpoint: Dose Limiting Toxicity at 4 weeks. Status: unknown.
02
Drugs
SH003
03
Conditions
lung cancerbreast cancer
Beyond the preview
Go deeper on NCT04360317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04360317.